Earlier this month saw the first new PPP active substance approval granted in Great Britain under the retained Regulation (EC) No 1107/2009.
The herbicidal active substance, cinmethylin, supported for approval by BASF plc, was formally approved in Great Britain on 7th June 2022 following the Health and Safety Executive’s (HSE) risk assessment of the substance and conclusion that it is expected to meet the criteria for approval.
It was wonderful to see so many of our clients, collaborators and friends at SETAC Europe in Copenhagen last month. For many of us it was the first chance in 2 years to get together in person. We hope you enjoyed it as much as we did!
There was a great spread of interesting scientific topics. One significant scientific advancement we noticed was the proliferation of TKTD modelling talks and posters beyond its usual home in the effects modelling session. This approach is starting to establish itself as a “go to” method for the future – a progression our ecotoxicologist Dr Alice Tagliati contributed too with two posters on the application of the approach in regulatory risk assessment.
We have received a number of queries recently relating to the use of UK efficacy trials in support of EU product registrations post Brexit. The question arises due to the UK no longer being an EU member state, and therefore no longer participating in the EU plant protection product registration programme under EU regulation 1107/2009.
Well, you can rest assured - The UK is still geographically part of Europe, and as such remains included in the maritime zone under EPPOs ‘zones of comparable climate’ as described in EPPO guidance PP 1/241 – Guidance on comparable climates.
2022 is the year we’re expecting to see the most significant updates to Endocrine Disruption assessments for REACH and BPR in over 5 years. Here we’ll talk about what’s coming and the steps you can take to make sure you’re prepared for these changes.
Poison Centre Notifications have been a legal requirement for many products since 1st January 2021. From a technical standpoint, completing a PCN submission doesn’t need the same scientific expertise required to complete a full product registration...however, collating and compiling the mandatory data for your PCN can be a time-consuming task and, as always, nuances within the online systems involved can make the process frustrating for the applicant.
Here we’ll look at the PCN submission process, the data requirements, and challenges to be aware of, ensuring that your PCN submissions are as stress-free as possible.
The 2022 field trial season is upon us and with it comes the challenges of managing these projects, from assessing efficacy data gaps and managing your trial programmes, through to compiling your Biological Assessment Dossier and other registration documents. It can be an onerous journey to navigate but if you’re looking for a partner to support you, we can help you every step of the way.
